Rayno BioBeat #4: Biotechs Weaken on Profit Taking…Update-2
Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week that the XBI be...
ACA: Uncertainty Remains After Healthcare Bill Failure But Stocks Get a Second Wind…Update-1
Update-1... JY 19...Biotech and Healthcare Stocks Continue to Rally IBB breaks through top to $322.92 up 21.68% YTD; XBI up 1.34% today 35.4% YTD; XLV up 17.6% YTD. Rayno Life Science top winners YTD: ABBV up 18.19%, AMGN up 22.6%, BLUE up 55% YTD, FMI up 114.7%, RHHBY up 12.86%. All beating...
Hot Fun in the Summertime: NYC Hits 92 degrees;Healthcare Plan Draft Out
Update after close 7/13: Health Care draft bill appears to have stabilized biotech despite opposition. ETFs end in green but XLV is flat. More analysis is coming tomorrow. ========= It's Vacation Time We are out on vaca until Monday the 17th. Here are some updates as of 11:15a Thursday:...
2017 Life Science Review #1: Big Biotech Gains for First Half
Big Biotech Gains for Stocks in First Half Rayno Life Science Picks Top Winners YTD: Foundation Medicine (FMI) up 124.6%, bluebird bio (BLUE) up 70.26%, XBI up 20.9%. Large cap winners since inception: Abbvie (ABBV) and Roche ADR (RHHBY). 6/27 Take some profits on XBI at $78. XBI is our top ETF...
Sector Rotation or Another Tech Wreck?
Tech Wreck Part 2? Or Just Profit Taking. Sector Rotation Away from Large Cap Growth (QQQ) to Value (XLF) Volatility Returns Tech and biotech stocks were hit from sector rotation with the NASDAQ down 2.18 % to and the QQQ down 2% to $136.75 as of mid-day trading. This is the second hit in June...